EN | RU
EN | RU

Help Support

Back

New update: In-human clinical trial of KCP506 gets regulatory approval for chronic neuropathic pain treatment

New update: In-human clinical trial of KCP506 gets regulatory approval for chronic neuropathic pain treatment New update: In-human clinical trial of KCP506 gets regulatory approval for chronic neuropathic pain treatment
New update: In-human clinical trial of KCP506 gets regulatory approval for chronic neuropathic pain treatment New update: In-human clinical trial of KCP506 gets regulatory approval for chronic neuropathic pain treatment

What's new?

Human clinical trials to assess the effectiveness of first-in-class α9α10 nicotinic acetylcholine receptor antagonist now approved.

As per an announcement by a clinical-stage biotechnology company on 12 August 2020 the Clinical Trial Application (CTA) has been approved in the Netherlands for initiation of a first-in-human clinical trial of KCP506 (first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist) for chronic neuropathic pain treatment.


The safety and efficacy of KCP506 will be evaluated in healthy individuals in this double-blind, placebo-controlled, single ascending dose and multiple ascending dose study. The phase 1 clinical trials of KCP506 have been scheduled later in 2020. This regulatory approval marks a critical milestone for this organization to evaluate the novel non-opioid in the clinic, mentioned the company’s CEO. KCP506 has been believed to have the probability of a disease-modifying therapy devoid of CNS side effects comprising addiction. The α9α10 nAChR antagonists have confirmed its strong anti-neuroinflammatory, pain-relieving potential and neuroprotective outcomes in many preclinical models. KCP506 have the potential of easing chronic pain progression. Different chronic neuropathic pain comprising of diabetic neuropathy, radiculopathy, chemotherapy-induced peripheral neuropathy may benefit from KCP506.


This biotechnology company collaborated with a subsidiary of Roche in April 2018 dedicated to developing first in class α9α10 nAChR antagonists for chronic pain treatment.

Source:

CISION- PR Newswire

Article:

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: